Pharmaceutical Benefits Scheme – new and amended listings

New and amended listings are being added to the Pharmaceutical Benefits Scheme (PBS). These changes will provide eligible Australians and overseas visitors with more affordable access to vital medicines.

Information update: this Budget measure is not subject to the passage of legislation.

Description of measure

New and amended listings are being added to the Pharmaceutical Benefits Scheme (PBS). These changes will provide eligible Australians and overseas visitors with more affordable access to vital medicines.

From 1 February 2016, the following medicines were listed:

  • fentanyl citrate – for the treatment of secondary pain relief for cancer treatment
  • flucloxicillin – for the treatment of staphylococcal and other Gram-positive coccal infections

From 1 March 2016, the following medicines were listed:

  • empagliflozin with metformin – for the treatment of type 2 diabetes mellitus
  • leuprorelin – for the treatment of prostate cancer

From 1 April 2016, the following medicines were listed:

  • atazanavir and cobicistat – for the treatment of HIV infection
  • itraconazole – for the treatment of systemic fungal infections
  • nadroparin calcium – for the treatment of deep vein thrombosis (DVT) associated with general or orthopaedic surgery and prevention of clotting during haemodialysis
  • netupitant and palonosetron – for the treatment of nausea and vomiting

From 1 May 2016, the following medicines were listed:

  • bendamustine – for the treatment of Non-Hodgkin’s lymphoma and mantle cell lymphoma
  • nivolumab – for the treatment of melanoma

From 1 January 2016, the following listing was amended

  • eculizumab – for the treatment of atypical haemolytic uraemic syndrome (aHUS) - change to restriction text

The following amendments for 1 February 2016 are part of the ongoing Post Market Reviews. This is where medicines have the associated restrictions amended to reduce administrative burden:

  • methylnaltrexone – for the treatment of pain in chemotherapy care
  • eight infant formulae

From 1 March 2016, the following listings were amended:

  • calcipotriol with betamethasone – for the treatment of chronic stable plaque psoriasis
  • empagliflozin – for the treatment of type 2 diabetes mellitus (triple oral therapy)
  • empagliflozin – for the treatment of type 2 diabetes mellitus (in combination with insulin)

From 1 April 2016, the following listings were amended:

  • arsenic – for the treatment of acute promyelocytic leukaemia
  • mesalazine – for the treatment of ulcerative colitis
  • dabrafenib and trametinib – for the treatment of unresectable stage III and stage IV malignant melanoma

The following amendment for 1 April 2016 is part of the ongoing Post Market Reviews:

  • antibiotics – for the treatment of infection

From 1 May 2016, the following listings were amended:

  • lapatinib and trastuzumab emtansine – for the treatment of breast cancer
  • bosentan, epoprostenol and macitentan – for the treatment of pulmonary arterial hypertension
  • ustekinumab – for the treatment of psoriatic arthritis

From 1 June 2016, the following listings will be amended:

  • omalizumab – for the treatment of severe allergic asthma

The following amendments for 1 June 2016 are part of the ongoing Post Market Reviews:

  • palliative care changes – for the group of medicines administered during a period of palliative care
  • medicinal foods changes – for the group of medicinal foods
  • optometric changes – for the group of ocular lubricants
  • miscellaneous changes – phenoxybenzamine and eribulin – for miscellaneous medicines

Questions and answers

Who is eligible for this measure

Eligible Australian residents and overseas visitors from countries under Reciprocal Health Care Agreements will be able to access these medicines under the PBS if prescribed by their health professional.

Patients pay part of the cost of a PBS medicine to the pharmacy at the time of supply. The maximum patient contribution rates are adjusted on 1 January each year in line with inflation.

The date this measure will start and finish

This measure started on 1 January 2016 and is ongoing.

Page last updated: 12 September 2016

This information was printed Thursday 8 December 2016 from humanservices.gov.au/corporate/budget/budget-2016-17/health-matters-and-health-professionals/pharmaceutical-benefits-scheme-new-and-amended-listings It may not include all of the relevant information on this topic. Please consider any relevant site notices at humanservices.gov.au/siteinformation when using this material.